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Male breast carcinoma: radiotherapy 
contributed to favorable local control in two 
cases and related literature review
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Abstract 
Male breast carcinoma (MBC) is rarely encountered in clinical practice. Due to its paucity, our knowledge of MBC only 
rely on small or single-institutional studies and sporadic cases. The current guidelines for MBC are extrapolated from 
its female counterparts Rudlowski (Breast Care (Basel) 3(3):183–189, 2008). Nowadays, MBC is actively studied and 
viewed as a potentially different entity on the aspects of etiology, biological behavior and prognosis. Thus, special 
treatment strategy guidelines should be established for MBC. Additionally, advance in the systemic chemotherapy 
and hormonal therapy also contribute to the local control. The indication of radiotherapy need to be clarified and 
over-treatment should be avoided. Here we present two cases of MBC in which radiotherapy help to sustain a satisfac-
tory disease free survival. Our cases will provide valuable experience for identifying the role of radiotherapy in MBC.
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Background
MBC is exceedingly rare, composing less than 1 % of all 
the breast cancer [1]. Despite increasing incidence in 
recent years [2], many aspects such as best intervention, 
prognostic factors and so on are still unclear. Here, we 
present two rare cases of MBC. In the former, adjuvant 
radiotherapy contributed to prevention of local relapse. 
In the latter, radiotherapy was effective in controlling the 
recurrence of chest wall and achieved a good disease free 
survival (DFS) of at least 28 months.
Case presentation
Case 1
A 53-year-old man presented in January, 2011 with a his-
tory of painless lump of left breast for about 5  months. 
On physical examination, a hard lump measuring about 
3.0  ×  2.5  cm was palpated in the left breast and an 
enlarged, irregular lymph node of 2.0 × 1.5 cm was pal-
pated in the left axilla. The breast ultrasound showed a 
3.33 × 2.07 cm hypoechoic lesion in the left breast with 
blood flows and a 1.61  ×  1.2  cm lymph node without 
normal structure. BI-RADS: 4b. The following Mam-
motome needle biopsy of left breast lump revealed inva-
sive ductal carcinoma (IDC) with immunohistochemical 
results of ER (40 %+), PR(−), Her-2(−). Relevant staging 
examination ruled out distant metastasis. Thus, a male 
breast IDC of IIB, cT2N1M0, was diagnosed.
First, the patient received neoadjuvant chemotherapy 
of five cycles of TAC (Docetaxel, Adriamycin and Cyclo-
phosphamide) and attained a near complete remission 
response. On 4th May, 2011, modified radical mastec-
tomy (MCM) was performed and definitive pathology 
showed only a little residual ductal carcinoma in situ with 
partial microinvasion. Left axillary dissection proved 
negative for nodal metastases (0/29). The tumor bed was 
1.5 ×  1.1 ×  1.0 cm and immunohistochemistry showed 
ER (40  %+), PR(−), Her-2(−). Then he received a cycle 
of TAC followed by adjuvant radiotherapy to left chest, 
supra and subclavicular region with a dose of 50 Gy/25f. 
Endocrine therapy was declined by the patient. To date, 
he lives a life of good quality and a 3-year DFS has been 
attained.
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Case 2
A 60-year-old man presented in April, 2010 with 1-month 
history of lump in right breast. Breast ultrasound dem-
onstrated a 1.67 × 1.19 cm hypoechoic mass in the right 
breast. The subsequent biopsy demonstrated breast car-
cinoma. Then he received MCM in another hospital. The 
postoperative pathology showed IDC of grade II, with 
component of small tube carcinoma and right axillary 
lymph node metastases (2/14). Immunohistochemistry 
showed ER(−), PR(−), Her-2(−). He was staged as IIA, 
pT1N1M0. Then he received 6 cycles of chemotherapy 
but didn’t receive radiotherapy. 15  months later, recur-
rence of chest wall occurred and local resection was per-
formed. The pathological results were as followings: IDC 
with invasion of pectoral muscle, vascular and nerve tis-
sue, Ki-67 (+30  %), ER (+60  %), PR(−), Her-2(−). The 
borders were positive. The patient took tamoxifen but 
refused radiotherapy. 4 months later, a 2.0 cm × 2.0 cm 
mass appeared on the chest wall near the previous recur-
rent site. Then radiotherapy with a dose of 70 Gy/35f to 
the recurrence and 50 Gy/25f to the chest wall was car-
ried out and the recurrent lesion disappeared. To date, 
DFS has reached to 28 months.
Discussion
MBC is rather rare, with a predilection of elder men [3]. 
Despite great improvement in breast cancer treatment 
recently, MBC benefit less than FBC [4]. According to 
Surveillance, Epidemiology and End Result (SEER) data 
analysis, survival of breast cancer patients between 1996 
and 2005 showed a 42 % decrease of breast cancer-spe-
cific death in female, but only a 28 % decrease in male [4, 
5]. Comparing with female counterpart, MBC demon-
strate more advanced stage-related tumor features such 
as 40 % stage III or IV disease [6] and 40–55 % axillary 
lymph node metastasis at first visit [7] and more tumor 
size >2.0  cm [8]. Interestingly, MBC manifested less 
advanced biology-related variables such as high tumor 
grade and ER or PR negativity [8]. IDC is the most com-
mon pathological type of MBC [9]. According to the 
multivariate analysis by Yoney et  al. [9], lymph node 
metastasis was significantly associated with a poor DFS 
and overall survival (OS).
Recently, MBC is increasingly recognized as a different 
disease from FBC. Research have been initiated to clar-
ify specific biomarkers of MBC pathogenesis. Genome-
wide microarray analysis revealed miR-10a, miR-10b, 
miR-125b, miR-126 and miR-191 were underexpressed 
in MBC samples while miR-26b, miR-135b and miR-607 
were overexpressed comparing with gynecomastia sam-
ples. As a target protein of miR-126, VEGF overexpressed 
correspondingly, partly contributing to the angiogen-
esis and progression of MBC. Comparing with FBC, 4 
miRNAs overexpressed and 13 underexpressed in MBC 
[10]. Compared to gynecomastia, prolactin receptor 
expression was remarkably higher in MBC [4, 11]. Sur-
vivin and COX-2 were expressed in a substantial propor-
tion of MBC individuals [4, 12]. In the near future, more 
specific miRNAs and genes will be identified in involve-
ment of MBC development and as novel therapeutic tar-
get consequently.
Due to the lack of adequate breast tissue, MBC tends 
to invade the pectoralis major muscle. MCM is recom-
mended as the standard surgical protocol to achieve 
R0 resection [13]. Sentinel lymph node (SLN) analy-
sis seemed to be reliable in MBC [8]. In early-staged 
patients, breast conserving surgery might be feasible [4, 
14].
In the past, radiotherapy was performed for all the 
postoperative MBC patients in view of inadequate sur-
gical margin due to the lack of breast tissue [13, 15]. Yu 
et  al. also indicated that postmastectomy radiotherapy 
(PMRT) bring significantly better local relapse free sur-
vival rather than OS benefit, especially for individuals 
with high risk factors such as ≤2 mm or unknown sur-
gical margin, advanced stage and lymph node metastasis 
[16]. Now, PMRT indication in MBC follow recommen-
dations for FBC, especially for those with axillary nodal 
involvement [17]. Besides, more MBC were inclined to 
PMRT than FBC for higher possibility of skin and nip-
ple involvement [18, 19]. Korde et  al. considered that 
retroareolar tumor or muscle invasion were also PMRT 
indication in MBC [8]. These two cases should be sub-
jected to PMRT due to the involvement of axillary lymph 
nodes. The timely radiotherapy after MCM contributed 
to long-term DFS in the first patient. However, in the sec-
ond case who didn’t receive PMRT, chest wall recurrence 
took place 15 months after surgery. The first 2 years was 
the peak of recurrence [9]. Radiotherapy after recurrence 
also played a critical role in local control. According to a 
20-year survival data for PMRT in MBC, stage III disease 
could obtain OS benefit from PMRT whereas stages I and 
II could not. However, the results of this retrospective 
research was questioned for adverse long-term effects in 
earlier stages caused by obsolete irradiation techniques 
impaired the OS benefits [20]. Advanced radiotherapy 
techniques nowadays will maximize the dose to target 
volume and minimize the dose of normal organs, which 
might transform to the OS benefit for early-staged MBC 
patients.
90  % MBC cases express hormonal receptor. Thus, 
hormonal treatment is a crucial part of the management 
strategy [21]. Tamoxifen contributes to improved DFS 
and OS [22]. The application of aromatase inhibitors in 
MBC is still worthy of scrutiny [2]. The main reason is 
that testicular production of estrogen is independent 
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of aromatase, composing about 20  % circulating estro-
gen [2, 23]. Furthermore, aromatase inhibitors has been 
reported to induce the increase of testosterone level 
providing more substrate for the production of estrogen 
[2, 24]. However, there is a high rate of discontinuation 
of tamoxifen in MBC due to one or more toxicity. Most 
common toxic effects are sexual dysfunction and weight 
gain [25]. In the second case, Tamoxifen alone failed to 
prevent the chest wall relapse while radiotherapy exerted 
favorable effect in local control. Because most of MBC 
patients are ER positive and older, adjuvant chemother-
apy can benefit MBC with high risks such as young age, 
endocrine-nonresponse, high tumor grade and multiple 
axillary lymph node involvement [8].
Because of its rarity, only limited reports of small sam-
ples or single institute can be reviewed [26]. Cutuli et al. 
analyzed 489 MBC cases in their institute and revealed 
the similar outcomes to FBC after early diagnosis and 
wide application of adjuvant treatments such as radio-
therapy, hormonal and chemotherapy [27]. However, 
biological differences between MBC and FBC should 
be emphasized and the treatment guidelines should not 
simply extrapolate FBC algorithms. In the future, col-
laboration of multiple institutions should be initiated 
and longer follow-up are fundamental for the full-scale 
research of this entity [26].
Conclusion
MBC is now recognized as an entity with a potentially 
different biology and special treatment algorithms for 
MBC should be established in the near future. Radio-
therapy indication for MBC patients need to be identi-
fied. Collaborative clinical trials are critical to clarify the 
optimal treatment for MBC.
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